INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd.

NEW YORK, March 09, 2020 -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of BeiGene, Ltd..

CAMBRIDGE, Mass. and BEIJING, China, March 02, 2020 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and.

Hutchison China MediTech (HCM) and BeiGene (BGNE) have now entered into a clinical collaboration agreement for the treatment of various solid tumor cancers.The collaboration will evaluate the safety, tolerability and efficacy of two of Chi-Med’s drug candidates, surufatinib and fruquintinib, combined with BeiGene’s anti-PD-1 antibody tislelizumab for cancer treatment in the US, Europe, China and Australia.Chi-Med and BeiGene each plan to explore development of the combination of these drug candidates in different indications and regions. The companies have agreed to provide mutual drug supply and other support.“We hope to understand and develop innovative combination therapies that may bring meaningful treatments to cancer patients around the world. Through this collaboration we plan to further evaluate tislelizumab in combination with oral VEGFR inhibitors to target a variety of solid tumor cancers,” said Lai Wang of BeiGene.Each of these three compounds are currently in late-stage global clinical development across many countries outside of China. Tislelizumab and fruquintinib have both been approved by the China National Medical Products Administration which is also currently reviewing the New Drug Application for surufatinib that was submitted late last year.Both companies currently score a bullish Strong Buy Street consensus. For instance, in the last three months, six analysts have published buy ratings on BeiGene vs 1 hold rating. With shares down 4% year-to-date, the average analyst price target indicates upside potential of 19%. (See BeiGene stock analysis on TipRanks).Maxim Group’s Jason McCarthy has a buy rating on BGNE with a $190 price target. He notes that Tislelizumab is currently being evaluated in 15 registration-enabling clinical trials in China and globally (11 P3 and 4 pivotal P2 trials).Related News: Novavax Begins Human Testing For Covid-19 Vaccine, Expects Results In July Regeneron and Sanofi’s Dupixent Shows ‘Positive’ Trial Data, Meets Co-Primary Endpoints Regeneron To Repurchase $5 Billion Stake From Sanofi   More recent articles from Smarter Analyst: * Data Center Set to Send Nvidia Stock Soaring Even Higher * Google Pay App May Face Anti-Trust Probe In India – Report * Trump Threatens Twitter After It Labels His Tweets "Potentially Misleading" * General Electric Surges 8% Amid Sale Of Lighting Unit To Savant

CAMBRIDGE, Mass., and BEIJING, China, May 15, 2020 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and.

CAMBRIDGE, Mass. and BEIJING, China, May 26, 2020 -- CAMBRIDGE, Mass. and BEIJING, China, May 22, 2020-- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage.

CAMBRIDGE, Mass. and BEIJING, China, May 11, 2020 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and.

– Collaboration to explore multiple solid tumor cancer indications – – Initial development focused on multi-cohort trials in the U.S., Europe, China.

CAMBRIDGE, Mass. and BEIJING, China, May 14, 2020 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and.

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the Phase 3 trial evaluating its anti-PD-1 antibody tislelizumab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of patients with non-squamous non-small cell lung cancer (NSCLC) met its primary endpoint, demonstrating a statistically significant improvement in progression-free survival (PFS) compared to pemetrexed and platinum chemotherapy alone at the planned interim analysis, as assessed by independent review committee (IRC). The safety profile of tislelizumab in combination with pemetrexed and platinum chemotherapy was consistent with the known risks of each study treatment, and no new safety signals were identified.

CAMBRIDGE, Mass. and BEIJING, China, April 29, 2020 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and.

CAMBRIDGE, Mass. and BEIJING, China, May 20, 2020 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and.

Simon Erickson of 7Investing.com joined the podcast this week to discuss the key metrics he uses to identify power growth stocks like Amazon and Tesla.

It could develop into a serious long-term problem for the pharmaceutical industry, which relies on clinical trials to get new drugs to the market.

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted a supplemental new drug application (sNDA) of BeiGene’s anti-PD-1 antibody tislelizumab in combination with two chemotherapy regimens for first-line treatment of patients with advanced squamous non-small cell lung cancer (NSCLC). “We look forward to working closely with the CDE on this filing and hope to bring a new treatment option to the large population of patients with advanced squamous NSCLC in China who could benefit from immunotherapy.”

CAMBRIDGE, Mass. and BEIJING, China and PETACH TIKVA, Israel, May 21, 2020 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on.

Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of BeiGene, Ltd. (NASDAQ: BGNE) resulting from allegations that BeiGene may have issued materially misleading business information to the investing public.

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that its anti-PD-1 antibody tislelizumab has received approval from the China National Medical Products Administration (NMPA) as a treatment for patients with locally advanced or metastatic urothelial carcinoma (UC) with PD-L1 high expression whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. Following tislelizumab’s initial approval in classical Hodgkin’s lymphoma (cHL) by the NMPA in December 2019, this is the second indication approved for tislelizumab, and the first in a solid tumor indication.

BEIJING, China, and CAMBRIDGE, Mass., March 25, 2020 (GLOBE NEWSWIRE) --  BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that, on March 25, 2020, the China National Medical Products Administration (NMPA) suspended the importation, sales and use of ABRAXANE® (nanoparticle albumin-bound paclitaxel) in China supplied to BeiGene by Celgene Corporation, a Bristol Myers Squibb (BMS) company. This suspension is based on inspection findings at BMS’s contract manufacturing facility in the United States.

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]